321 related articles for article (PubMed ID: 34481962)
1. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2021 Nov; 47(6):101275. PubMed ID: 34481962
[TBL] [Abstract][Full Text] [Related]
2. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
3. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
Scheen AJ
Presse Med; 2023 Mar; 52(1):104158. PubMed ID: 36565754
[TBL] [Abstract][Full Text] [Related]
5. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
Scheen AJ
Diabetes Metab; 2021 Jul; 47(4):101209. PubMed ID: 33189895
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
Scheen AJ; Bonnet F
Diabetes Metab; 2023 Mar; 49(2):101419. PubMed ID: 36640828
[TBL] [Abstract][Full Text] [Related]
8. The safety of gliptins : updated data in 2018.
Scheen AJ
Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study.
Aloe S; Filliter C; Salmasi S; Igweokpala S; Yu OHY; Tagalakis V; Filion KB
Br J Clin Pharmacol; 2023 Sep; 89(9):2902-2914. PubMed ID: 37183930
[TBL] [Abstract][Full Text] [Related]
10. Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Hu J; Chen L
Prim Care Diabetes; 2021 Apr; 15(2):227-233. PubMed ID: 32888896
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis.
Wang S; Wu T; Zuo Z; Jin P; Luo X; Deng M
Eur J Prev Cardiol; 2022 Jan; 28(16):1840-1849. PubMed ID: 34136913
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
14. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
16. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
17. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Scheen AJ
Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
[No Abstract] [Full Text] [Related]
18. An update on the safety of SGLT2 inhibitors.
Scheen AJ
Expert Opin Drug Saf; 2019 Apr; 18(4):295-311. PubMed ID: 30933547
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
Xu S; Zhang X; Tang L; Zhang F; Tong N
Postgrad Med; 2017 Mar; 129(2):205-215. PubMed ID: 27813442
[TBL] [Abstract][Full Text] [Related]
20. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
Scheen AJ
Diabetes Metab; 2022 Mar; 48(2):101325. PubMed ID: 35121148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
